Patient Outcomes in Rheumatoid Arthritis
|
|
- Rodger Banks
- 5 years ago
- Views:
Transcription
1 Patient Outcomes in Rheumatoid Arthritis
2 The impact of rheumatoid arthritis on patients quality of life A small qualitative study involving 25 patients with rheumatoid arthritis in Sweden looked at the outcomes from treatments that patients considered to be the most important in terms of their quality of life and general well-being. 7 The researchers held focus groups at four hospitals. Outcomes that patients identified as being the most important to them included: 7 Shared decision-making between the patient, clinicians and other healthcare professionals has been recognised as a fundamental part of the treatment strategy for rheumatoid arthritis. 1 Clinical remission is the primary target of treatment, although low disease activity is considered to be an acceptable alternative, particularly if the patient has longstanding disease. 1 Recommendations from an international task force emphasise the importance of giving patients information about the potential benefits and risks of treatment in order to achieve the treatment target. 1 In 2011 an international steering group of rheumatologists and patients developed a patient version of the original recommendations from the task force (published in ) to facilitate the shared decision-making process and support treatment adherence. 3 Ensuring the patient is well informed about the risks of having rheumatoid arthritis, the implications of tight control as a treatment strategy and anticipated outcomes is important for achieving adherence. 3 However, there is evidence to suggest that patients and clinicians differ in their assessment of treatment outcomes 4 and disease activity. 5 Discrepancies between patients and clinicians assessments of physical function have been a long-standing concern. 6 being able to live a normal life and regain full health. Patients did not want to feel limited in their ability to carry out household tasks or participate in social activities. a reduction in pain and stiffness and an increase in mobility. Patients also mentioned the impact of fatigue on their physical capacity and some patients mentioned that they felt unable to do anything because of fatigue. maintaining their independence patients emphasised the importance of being able to manage daily tasks such as dressing themselves, managing the household, caring for their families and managing work 7. In another small qualitative study that evaluated the possible reasons for discrepancies between patients and clinicians perceptions of disease activity, patients mentioned that they often avoided participating in certain activities because they knew that the activities would cause pain. 8 They felt that having to make adjustments in their daily life was a loss. Some patients felt that medical treatment had a negative impact on their general wellbeing and they thought that the side effects of treatment were a possible cause of fatigue. 8 The development of patient-reported outcomes The ability to accurately assess the extent of disease activity is crucial for determining the severity of disease and monitoring the effects of treatment in patients with rheumatoid arthritis. 9 Concordance between patients and physicians assessments of the activity of disease is vital if patients are to be managed safely and effectively. 9 The assessment of the severity of disease is dependent on subjective measures (e.g. how the patient thinks their arthritis is progressing) as well as objective measures (e.g. the number of swollen joints, the levels of acute phase reactants). 9 Patient-reported outcomes (PROs) are becoming increasingly important in trials and clinical practice because they provide information about how the patient views specific aspects of their disease and their overall health. 10 The emphasis on shared decision-making 1 and consideration of the patient s perception of health when developing management plans means that PROs may have a key role to play in the routine assessment of patients in clinical practice (as well as providing an outcome measure in clinical trials). 10 The development of core sets of variables and indexes, such as the Disease Activity Score (DAS), that combine objective measures with PROs has helped to facilitate the standardised measurement of disease activity in clinical trials. 11 The value of involving patients in the development of patient-reported outcome measures has recently been recognised. 12 For example, fatigue is now considered to be an important outcome measure. 12 One study found that 80% of patients suffer with fatigue and over 50% have high levels of
3 fatigue. 13 At a series of OMERACT conferences patients highlighted that healthcare professionals did not appear to recognise that fatigue was a significant symptom for them. 14 As a result of these discussions fatigue is now recognised as an important outcome measure to consider in clinical trials. 15 The potential effects of discordance in clinical practice If there is discordance between clinicians and patients assessments of disease activity and severity it may affect the shared decisionmaking process and the effectiveness of treatment. 16 Discrepancies between assessments of disease activity may lead to conflict between which outcome measure should be guiding decisions about treatment. 17 Discordance between perceptions of physical functioning could lead to healthcare providers recommending treatments for patients that are unnecessary or not recommending interventions for patients where needed. 6 The authors looked at proportional changes between the two scores and concordance in perceptions of changes in disease activity following treatment (i.e. whether disease activity had improved, worsened or remained the same). They found that: 16 42% of patients thought disease activity was better after starting treatment and 45% of clinicians thought the same; 37% of patients thought there was no change in their disease activity compared to 27% of clinicians; and 21% of patients thought that disease activity had worsened compared to 28% of clinicians. What are the possible reasons for these discrepancies? A longitudinal and cross-sectional study of 646 patients with rheumatoid arthritis who were taking methotrexate examined the possible causes for discordance between patients and clinicians assessments of disease activity. 16 The authors examined: 16 variables that correlated with the Patient Global Assessment (PGA) and the Evaluators Global Assessment (EGA) (e.g. pain, swollen joints); the determinants of discrepancies between the PGA and EGA; and the determinants of discrepancies in improvement between the PGA and EGA. There was a strong correlation between pain scores and the PGA (r = 0.86, p <0.001) and the number of swollen joints with the EGA (r = 0.77, p <0.01). A multivariate analysis found that pain explained 75.6% of the variation in the PGA. 16 The following variables showed a significant association with the degree of discrepancy between the PGA and EGA scores: 16 number of swollen joints (r = -0.39); pain score (r = 0.62); Health Assessment Questionnaire (HAQ) score (r = 0.26); number of joints that were tender (r = 0.15); and the duration of morning stiffness (r = 0.21). (For each variable p <0.001.) The negative correlation for swollen joints indicates that in patients with a higher number of swollen joints, clinicians had a worse perception of the severity of disease than the patients did. Pain scores and the number of swollen joints were the only variables found to be independently associated with discrepancies between the PGA and EGA (p <0.001). 16 The changes that occurred between the PGA and EGA scores during the study period were found to be significant (p <0.001). 16 Perceptions of improvement in disease activity showed the highest concordance. Patients who were perceived to have improved had the highest baseline PGA and EGA scores. They also had the biggest changes in the pain score and the number of swollen joints and tender joints. Where patients and clinicians perceived that the disease activity had worsened, the concordance was lower. 16 The pain score, the number of swollen joints and the number of tender joints appeared to be the main determinants of the changes seen in the PGA and EGA scores ( r 2 = 0.346, r 2 = and r 2 = respectively). 16 Overall, the study found that pain appears to be the most important determinant of a patient s perceptions of disease activity. The most important determinant of disease activity for clinicians appeared to be the number of swollen joints. A multivariate analysis of the data suggests that patients assess their disease activity as worse than physicians do. 16
4 The authors emphasise the importance of understanding the patient s priorities for management when making treatment decisions because the problems they face may not be a direct result of joint disease. Co-existing conditions and chronic damage may also be an issue and this is particularly relevant for pain that is not caused by joint inflammation. Reducing non-inflammatory pain may help to increase concordance between patients and physicians assessments of disease activity and facilitate shared decisionmaking about the need for further treatments. 16 Another study looking at the degree of discordance between clinicians and physicians assessments of the severity of disease found that 31% of patients differed from clinicians in their perceptions of disease severity. 16 The authors used the visual analogue scale (VAS) to measure global disease severity and looked at: 9 disease characteristics (rheumatoid factor, number of swollen and tender joints, ESR and DAS 28 score); functional status (measured using the HAQ); and symptoms of depression (measured using the Patient Health Questionnaire 9 (PHQ-9)). The results showed: 9 a positive discordance in 31% of the patient physician dyads (patient physician difference of >25 mm on the VAS); a negative discordance in 5% ( less than -25 mm on the VAS); concordance in 64% (<25 mm on the VAS). Symptoms of depression were an independent predictor of positive discordance (AOR 1.62, 95% CI ). 9 The authors hypothesise that the association between depression and discordance may be due to poor communication between the patient and clinician, but they recognise that further research is needed in this area. 9 The study also found a difference between mean scores for the Disease Activity Score (DAS) 28-4 variable and DAS 28-3 variable (which was calculated without the patient global assessment of disease severity) that was statistically significant (p = for concordant groups, p <0.001 for positive discordant groups and p = for negative discordant groups). 9 Patients with positive discordance had a mean DAS 28-3 score that was on average 0.54 lower compared to concordant patients whose score was an average of 0.08 lower. 9 These differences suggest that DAS 28 score may not be an accurate reflection of the activity of disease in patients with positive discordance. 16 The association between depression and discordance may have an effect on DAS 28 scores. DAS 28 scores that indicate moderate to high disease activity may result in clinicians starting more intensive treatment when the patient s disease activity could potentially be more influenced by symptoms of depression rather that any joint pain or swelling. 9 Alternatively, there may be a mechanism whereby depression itself affects the efficacy of treatment so that the perception of response to treatment is not as great as it otherwise would be (which would be reflected in the DAS 28 score). 9 Evidence has shown that depression may affect a patient s response to treatment and the way in which they report symptoms. 18 A study looking at the prevalence of depression in 159 patients starting treatment with anti-tnf drugs found that 47.5% of patients were depressed at baseline. The percentage of patients who remained depressed (but continued with treatment) fell to 15% at 12 months. Five patients were diagnosed with depression over the study period. 18 Patients who were depressed at baseline had higher DAS 28 scores than those who were not depressed but this difference was not statistically significant at 12 months (p = 0.42). 18 Treatment with anti-tnf therapy appeared to have less effect on disease activity in patients with persistent depression compared to patients who were not depressed. At three months, patients with persistent depression had a lower reduction in the DAS 28 score than people who did not have depression (median (interquartile range) change DAS (0 2.6) vs 2.2 ( ) p = 0.005). 18 An explanation for this might be the effect that symptoms of depression have on objective and subjective measures of inflammation. For example, the 28-swollen-joint-count at three months in depressed patients was 7 compared to 4 in patients who did not have depression (p = 0.006). 18 The 28-tender-joint-count at three months was 9 in depressed patients compared to 5 for patients without depression (p = 0.001). 18 These findings suggest that patients with depression, particularly those with persistent symptoms, do not respond as well to treatment with anti-tnf therapy. Managing depression in these patients may help to improve the effectiveness of treatment. 18 Further studies are needed to examine the effect of discordance on the assessment of disease activity (particularly on the DAS 28 scores) and to look at the effect of depression on communication between patients and healthcare providers. 9 Factors to consider when using patient-reported outcomes Patient-reported outcomes (PROs) are useful because they provide information about the patient s perspective on aspects of their disease. Measurement of objective outcomes, such as pain and fatigue, are seen as important by patients and so it would follow that these outcomes should be reported by patients themselves. 17 Patient-reported outcome measures that assess functional limitations and symptoms are of most interest clinically because they are indicative of the severity of a disease and provide information about the response to treatments. 19 Discordance between patients and clinicians assessments of disease activity may have an adverse effect on treatment decisions, 16,17 but an argument has been made that, in some instances, discordance could help to guide treatment decisions. For example, if a patient is experiencing a lot of symptoms but there is no evidence of inflammation this could lead to a decision to make changes in treatments that modify symptoms rather than making changes to any disease-modifying treatments. 17 There are challenges with using some PROs to assess the efficacy of treatments because the link between them and the pathophysiology and treatment of rheumatoid arthritis is not clear. Further research is needed to establish how useful PROs are at predicting long-term outcomes and how to approach discordance when making treatment decisions. 17
5 References 1. Smolen J, Breedveld FC, Burmester GR, Bykerk V et al. Treating rheumatoid arthritis to target: 2014 update of the recommendation of an international task force. Clinical and epidemiological research. Ann Rheum Dis doi: /annrheumdis Smolen JS, Aletaha D, Bijlsma WJ, Breedveld et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69: doi: /ard de Wit MPT, Smolen JS, Gossec L, van der Heijde DMFM. Treating rheumatoid arthritis to target: the patient version of the international recommendations. Ann Rheum Dis 2011; 70: doi: /ard Physician Discordance in Assessments of Global Disease Severity in Rheumatoid Arthritis. Arthritis Care Res. 2010;62(6): doi: /acr Smolen JS, Strand V, Koenig AS, Szumsk A et al. Discordance between patient and physician assessment of global disease activity in rheumatoid arthritis and association with work productivity. Arthritis Res Ther :114 doi: /s Berkanovic E, Hurwicz ML, Lachenbruch PA. Concordant and discrepant views of patients physical functioning. Arthritis Care Res 1995; 8: Ahlmén M, Nordenskiold U, Archenholtz B, Thybert I et al. Rheumatology outcomes: the patient s perspective. A multicenter focus group interview study of Swedish rheumatoid arthritis patients. Rheumatology (Oxford) 2005 Jan; 44(1): Walter MJ, Van t Spijker A, Pasma A, Hazes JM, Luime JJ. Focus group interviews reveal reasons for differences in the perception of disease activity in rheumatoid arthritis. Qual Life Res. 2017;26(2): doi: /s Barton JL, Imboden J, Graf J, Glidden D, Yelin EH, Schillinger D. Patient Physician Discordance in Assessments of Global Disease Severity in Rheumatoid Arthritis. Arthritis Care Res. 2010;62(6): doi: /acr Nikiphorou E, Radner H, Chatzidionysiou K, et al. Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. Arthritis Res Ther. 2016;18:251. doi: /s Sanderson T, Morris M, Calnan M, Richards P, Hewlett S. What outcomes from pharmacological treatments are important to people with rheumatoid arthritis? Creating the basis of a patient core set. Arthritis Care Res. 2010;62(5): doi: /acr de Wit MPT, Kvien TK, Gossec L. Patient participation as an integral part of patient-reported outcomes development ensures the representation of the patient voice: a case study from the field of rheumatology. RMD Open 2015; 1:e Doi: /rmdopen Pollard LC, Choy EH, Gonzalez J, Khoshaba B, Scott DL. Fatigue in rheumatoid arthritis reflects pain not disease activity. Rheumatology (Oxford) 2006 Jul;45(7):885-9 Epub 2006 Jan de Wit M, Abma T, Koelewijn-van Loon M, et al. Involving patient research partners has a significant impact on outcomes research: a responsive evaluation of the international OMERACT conferences. BMJ Open 2013;3:e doi: /bmjopen Kirwan JR, Minnock P, Adebajo A, et al. Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. J Rheumatol 2007;34: Studenic P, Radner H, Smolen JS, and Aletaha D. Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. Arthritis & Rheumatism, 2012; 64: doi: /art Gossec L, Dougados M, Dixon W. Patient reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open 2015;1:e doi: / rmdopen Hider SL, Tanveer W, Brownfield A, Mattey DL, Packham JC. Depression in RA patients treated with anti-tnf is common and under-recognized in the rheumatology clinic. Rheumatology (oxford) 2009 Sep;48(9): McKenna S. Measuring patient reported outcomes: moving beyond misplaced common sense to hard science. BMC Medicine ;86 doi: / PP-ENB-GBR-0449 August 2017
Citation for final published version:
This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: http://orca.cf.ac.uk/97756/ This is the author s version of a work that was submitted to / accepted
More informationAssessing Remission in Rheumatoid Arthritis on the Basis of Patient Reported Outcomes
136 Bulletin of the Hospital for Joint Diseases 2014;72(2):136-41 Assessing Remission in Rheumatoid Arthritis on the Basis of Patient Reported Outcomes Advantages of Using RAPID3/MDHAQ in Routine Care
More informationThe Patient Global Assessment of Disease Activity in Rheumatoid Arthritis: Identification of Underlying Latent Factors
Rheumatol Ther (2017) 4:201 208 DOI 10.1007/s40744-017-0063-5 BRIEF REPORT The Patient Global Assessment of Disease Activity in Rheumatoid Arthritis: Identification of Underlying Latent Factors Divya N.
More informationPerformance of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients under biological therapies
Performance of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients under biological therapies 1. Introduction The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a new instrument
More informationIn patients with inflammatory conditions, including rheumatoid
ORIGINAL ARTICLE Comparison of Physician and Patient Global Assessments Over Time in Patients With Rheumatoid Arthritis A Retrospective Analysis From the RADIUS Cohort Joseph A. Markenson, MD, FACP,* Andrew
More informationThe provisional ACR/EULAR definition of remission in RA: a comment on the patient global assessment criterion
RHEUMATOLOGY Rheumatology 2012;51:1076 1080 doi:10.1093/rheumatology/ker425 Advance Access publication 1 February 2012 CLINICAL SCIENCE Concise report The provisional ACR/EULAR definition of remission
More informationA 3-page standard protocol to evaluate rheumatoid arthritis (SPERA): Efficient capture of essential data for clinical trials and observational studies
A 3-page standard protocol to evaluate rheumatoid arthritis (SPERA): Efficient capture of essential data for clinical trials and observational studies T. Pincus Division of Rheumatology and Immunology,
More informationM. Schoels 1, F. Alasti 2, J. S. Smolen 1,2 and D. Aletaha 2*
Schoels et al. Arthritis Research & Therapy (2017) 19:155 DOI 10.1186/s13075-017-1346-5 RESEARCH ARTICLE Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28)
More information10/30/2013. Disclosures. Defining Flares in RA RA Flare Group
Disclosures Using PROMIS Instruments to Identify Disease Flares in People with Rheumatoid Arthritis S Bartlett is the Canadian delegate for PROMIS International Recipient of CIHR planning award for Canada
More informationFatigue in rheumatoid arthritis reflects pain, not disease activity
Rheumatology 2006;45:885 889 Advance Access publication 31 January 2006 doi:10.1093/rheumatology/kel021 Concise Report Fatigue in rheumatoid arthritis reflects pain, not disease activity L. C. Pollard,
More informationFaith Matcham, Sam Norton, David L Scott, Sophia Steer, Matthew Hotopf FA I T H M AT C H A M P H D S T U D E N T,
The impact of baseline and persistent symptoms of depression and anxiety on long-term physical health outcomes and response to treatment in Rheumatoid Arthritis Faith Matcham, Sam Norton, David L Scott,
More informationReceived: 27 May 2003 Revisions requested: 26 Jun 2003 Revisions received: 14 Aug 2003 Accepted: 19 Aug 2003 Published: 1 Oct 2003
Research article Etanercept versus etanercept plus methotrexate: a registrybased study suggesting that the combination is clinically more efficacious Ronald F van Vollenhoven 1, Sofia Ernestam 2, Anders
More information5/4/2018. Outcome Measures in Spondyloarthritis. Learning Objectives. Outcome Measures Clinical Outcome Assessments
Outcome Measures in Spondyloarthritis Marina N Magrey MD Associate Professor Case Western Reserve University School of Medicine at MetroHealth Medical Center Learning Objectives What are outcome measures
More informationTreat - to - Target Pathway Commissioning Chronic and Complex Care MIDLANDS RHEUMATOLOGY & MUSCULOSKELETAL (MSK) COMMISSIONING NETWORK
Treat - to - Target Pathway Commissioning Chronic and Complex Care MIDLANDS RHEUMATOLOGY & MUSCULOSKELETAL (MSK) COMMISSIONING NETWORK Dr Bruce Kirkham Consultant Rheumatologist Guy s & St Thomas NHS Foundation
More informationRADAI-5 and electronic monitoring tools
RADAI-5 and electronic monitoring tools B.F. Leeb 1,2, H.-P. Brezinschek 2, B. Rintelen 1 1 2 nd Dept. of Medicine, Center for Rheumatology Lower Austria, Karl Landsteiner Institute for Clinical Rheumatology,
More informationTitle: The ideal target for psoriatic arthritis? Comparison of remission and low
Title: The ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real life cohort. Leonieke J.J. van Mens, MD 1, Marleen G.H. van de Sande, MD 1, PhD 1, Arno
More informationNEAR STUDY: NEEDS AND E XPECTATIONS IN R HEUMATOID ARTHRITIS DO WE KNOW OUR
ARTIGO ORIGINAL NEAR STUDY: NEEDS AND E XPECTATIONS IN R HEUMATOID ARTHRITIS DO WE KNOW OUR PATIENTS NEEDS? Luís Cunha-Miranda *, Lúcia Costa **, José Saraiva Ribeiro *** Abstract Introduction: Rheumatoid
More informationImpact of intensive treatment and remission on health-related quality of life in early and established rheumatoid arthritis
To cite: Scott IC, Ibrahim F, Lewis CM, et al. Impact of intensive treatment and remission on health-related quality of life in early and established rheumatoid arthritis. RMD Open 2016;2: e000270. doi:10.1136/
More informationDiscordance between physician s and parent s global assessments in juvenile idiopathic arthritis
Rheumatology 2007;46:141 145 Advance Access publication 16 June 2006 Discordance between physician s and parent s global assessments in juvenile idiopathic arthritis doi:10.1093/rheumatology/kel201 F.
More informationPhysical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients
Radner et al. Arthritis Research & Therapy (2015) 17:203 DOI 10.1186/s13075-015-0719-x RESEARCH ARTICLE Open Access Physical function continues to improve when clinical remission is sustained in rheumatoid
More informationReview of the Psoriatic Arthritis working group at OMERACT 12: a report from the. GRAPPA 2014 annual meeting
Review of the Psoriatic Arthritis working group at OMERACT 12: a report from the GRAPPA 2014 annual meeting W. Tillett L. Eder N. Goel M. dewit A. Ogdie AM Orbai W. Campbell O. FitzGerald N. McHugh D.
More informationJ. van Aken* H. van Dongen* S. le Cessie F.C. Breedveld T.W.J. Huizinga. * both authors contributed equally
CHAPTER Comparison of long term outcome of patients with rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis: an observational cohort study J. van Aken* H. van
More informationComprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis?
Handling editor Tore K Kvien 1 Leeds Institute of Rheumatic & Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching
More informationJuvenile Idiopathic Arthritis in Adults: Long-Term Observation of Ukrainian Patients
Archive of Clinical Medicine 2017 Vol. 23, Issue 1, E201715 DOI: 10.21802/acm.2017.1.5 Research Article Juvenile Idiopathic Arthritis in Adults: Long-Term Observation of Ukrainian Patients Marta Dzhus
More informationGlenn Haugeberg 1,2*, Brigitte Michelsen 1, Stig Tengesdal 1, Inger Johanne Widding Hansen 1, Andreas Diamantopoulos 3 and Arthur Kavanaugh 4
Haugeberg et al. Arthritis Research & Therapy (2018) 20:160 https://doi.org/10.1186/s13075-018-1659-z RESEARCH ARTICLE Open Access Ten years of follow-up data in psoriatic arthritis: results based on standardized
More informationRheumatoid arthritis 2010: Treatment and monitoring
October 12, 2010 By Yusuf Yazici, MD [1] The significant changes in the way rheumatoid arthritis has been managed include earlier, more aggressive treatment with combination therapy. Significant changes
More informationBringing the clinical experience with anakinra to the patient
Rheumatology 2003;42(Suppl. 2):ii36 ii40 doi:10.1093/rheumatology/keg331, available online at www.rheumatology.oupjournals.org Bringing the clinical experience with anakinra to the patient S. B. Cohen
More informationPrincipal Investigator. General Information. Conflict of Interest. Certification Published on The YODA Project (
Principal Investigator First Name: Liana Last Name: Fraenkel Degree: MD, MPH Primary Affiliation: Yale University School of Medicine E-mail: christine.ramsey@gmail.com Phone number: 610-613-6745 Address:
More informationAoyagi, Kiyoshi; Eguchi, Katsumi; K
NAOSITE: Nagasaki University's Ac Title Author(s) Combination of MRI-detected bone ma arthritis classification criteria i rheumatoid arthritis Tamai, Mami; Kita, Junko; Nakashima Horai, Yoshiro; Okada,
More informationABSTRACT Objective: To evaluate effects of the anti-interleukin-6 receptor monoclonal antibody sarilumab administered
To cite: Strand V, Reaney M, Chen C-I, et al. Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/ intolerance to tumour necrosis factor inhibitors. RMD
More informationMedication Prior Authorization Form
Policy Number: 1055 Policy History Approve Date: 06/01/2018 Effective Date: 06/01/2018 Preauthorization All Plans Benefit plans vary in coverage and some plans may not provide coverage for certain service(s)
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/23314
More informationConcordance with the British Society of Rheumatology (BSR) 2010 recommendations on eligibility criteria for the first biologic agent
Concordance with the British Society of Rheumatology (BSR) 2010 recommendations on eligibility criteria for the first biologic agent Michela Frendo, John Paul Caruana Galizia, Andrew A Borg Abstract Aims:
More informationNew Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
New Evidence reports on presentations given at EULAR 2011 Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2011 presentations Benefit of continuing
More informationACR ARHP. The Need for Patient Assessment Tools for Early Detection of Flares. Individualizing Patient Care in Rheumatoid Arthritis:
R E P O R T F R O M ACR ARHP 2008 Annual Scientific Meeting Individualizing Patient Care in Rheumatoid Arthritis: The Need for Patient Assessment Tools for Early Detection of Flares CAnadian Vision for
More informationK. Laas 1, R. Peltomaa 1, K. Puolakka 2, H. Kautiainen 3, M. Leirisalo-Repo 1
Early improvement of health-related quality of life during treatment with etanercept and adalimumab in patients with rheumatoid arthritis in routine practice K. Laas 1, R. Peltomaa 1, K. Puolakka 2, H.
More informationTHE BATH ANKYLOSING SPONDYLITIS PATIENT GLOBAL SCORE (BAS-G)
British Journal of Rheumatology 1996;35:66-71 THE BATH ANKYLOSING SPONDYLITIS PATIENT GLOBAL SCORE (BAS-G) S. D. JONES, A. STEINER,* S. L. GARRETT and A. CALIN Royal National Hospital for Rheumatic Diseases,
More informationTHE GAP BETWEEN ARTHRITIS HEALTH CARE PROVIDERS AND PATIENTS MAY arthritis.ca
THE GAP BETWEEN ARTHRITIS HEALTH CARE PROVIDERS AND PATIENTS MAY 2017 arthritis.ca 2 THE GAP BETWEEN ARTHRITIS HEALTH CARE PROVIDERS AND PATIENTS MAY 2017 TABLE OF CONTENTS THE GAP BETWEEN ARTHRITIS HEALTH
More informationPrimary Results Citation 2
Table S1. Adalimumab clinical trials 1 ClinicalTrials.gov Rheumatoid Arthritis 3 NCT00195663 Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study. A multicenter, randomized, double-blind clinical
More informationMeasurement of stiffness in patients with rheumatoid arthritis in low disease activity or remission: a systematic review
van Tuyl et al. BMC Musculoskeletal Disorders 2014, 15:28 RESEARCH ARTICLE Open Access Measurement of stiffness in patients with rheumatoid arthritis in low disease activity or remission: a systematic
More informationII. Requirements Date RFP Issued: 07/11/2013 Use of Patient-Reported Outcome Measures in Management of Rheumatoid Arthritis (RA) I.
Pfizer Independent Grants for Learning & Change Request for Proposals (RFP) Rheumatoid Arthritis Patient-Reported Outcome Measures in Management of Rheumatoid Arthritis I. Background The mission of Pfizer
More informationO ver recent years, major changes have occurred in the
191 EXTENDED REPORT Seven year changes in health status and priorities for improvement of health in patients with rheumatoid arthritis T Heiberg, A Finset, T Uhlig, T K Kvien... See end of article for
More informationThe BeSt way of withdrawing biologic agents
The BeSt way of withdrawing biologic agents C.F. Allaart 1, W.F. Lems 2, T.W.J. Huizinga 1 1 Department of Rheumatology, Leiden University Medical Center, Leiden; 2 Department of Rheumatology, Free University
More informationTREAT-TO-TARGET IN RHEUMATOID ARTHRITIS
TREAT-TO-TARGET IN RHEUMATOID ARTHRITIS To receive up to 10 CME credits for this activity, complete the evaluation, attestation and post-test answer sheet (minimum passing grade of 70%) and return all
More informationJOINT ASSESSMENT IN RHEUMATOID ARTHRITIS
British Journal of Rheumatology 1996;35(suppl.2):14-18 JOINT ASSESSMENT IN RHEUMATOID ARTHRITIS D. L. SCOTT and D. A. HOUSSIEN Academic Rheumatology Unit, King's College School of Medicine and Dentistry,
More informationJOINT ASSESSMENT IN RHEUMATOID ARTHRITIS
British Journal of Rheumatology 1996;35(suppl.2):14-18 JOINT ASSESSMENT IN RHEUMATOID ARTHRITIS D. L. SCOTT and D. A. HOUSSIEN Academic Rheumatology Unit, King's College School of Medicine and Dentistry,
More informationORIGINAL ARTICLE. Rheumatoid arthritis
To cite: Tanaka Y, Yamanaka H, Ishiguro N, et al. Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab:
More informationWAIT TIMES TO RHEUMATOLOGY AND REHABILITATION SERVICES: IS RHEUMATOID ARTHRITIS PRIORITIZED?
WAIT TIMES TO RHEUMATOLOGY AND REHABILITATION SERVICES: IS RHEUMATOID ARTHRITIS PRIORITIZED? Ashley Delaurier PT M.Sc. Candidate Biomedical Sciences University of Montreal ashley.delaurier@umontreal.ca
More informationCHAPTER 4. S. Hirata 1, 2 L. Dirven 1 Y. Shen 3 M. Centola 4 G. Cavet 3 W.F. Lems 5 Y. Tanaka 2 T.W.J. Huizinga 1 C.F. Allaart 1
CHAPTER 4. A multi-biomarker based disease activity (MBDA) score system compared to a conventional disease activity score (DAS) system in the BeSt rheumatoid arthritis (RA) study S. Hirata 1, 2 L. Dirven
More informationQUALITY OF LIFE OF PATIENTS WITH RHEUMATOID ARTHRITIS IN BULGARIA
22 PHARMACIA, vol. 63, No. 2/2016 L. Marinov, I. Nikolova, K. Mitov, M. Kamusheva, G. Petrova QUALITY OF LIFE OF PATIENTS WITH RHEUMATOID ARTHRITIS IN BULGARIA L. Marinov 1, I. Nikolova 1, K. Mitov 2,
More informationImpact of obesity on rheumatoid arthritis: Relation with disease activity, joint damage, functional impairment and response to therapy
International Journal of Clinical Rheumatology Impact of obesity on rheumatoid arthritis: Relation with disease activity, joint damage, functional impairment and response to therapy Background and Aim
More informationThe new ACR/EULAR classification criteria for RA: how are the new criteria performing in the clinic?
RHEUMATOLOGY Rheumatology 2012;51:vi10 vi15 doi:10.1093/rheumatology/kes280 The new ACR/EULAR classification criteria for RA: how are the new criteria performing in the clinic? Vivian P. Bykerk 1,2 and
More informationAnnual European Congress of Rheumatology (EULAR) Madrid, Spain, June 2017
Annual European Congress of Rheumatology (EULAR) 2017 Madrid, Spain, 14-17 June 2017 NEW DATA SUGGEST NO INCREASED CANCER RISK FOR RA PATIENTS PRESCRIBED BIOLOGICAL DMARDS Reassuring findings may positively
More informationNew Evidence reports on presentations given at EULAR Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate
New Evidence reports on presentations given at EULAR 2009 Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate Report on EULAR 2009 presentations Tocilizumab inhibits
More informationDeterminants of Disability in Rheumatoid Arthritis: A Community-Based Cohort Study
Send Orders for Reprints to reprints@benthamscience.ae 88 The Open Rheumatology Journal, 2015, 9, 88-93 Open Access Determinants of Disability in Rheumatoid Arthritis: A Community-Based Cohort Study Megan
More informationOutcomes Research in Rheumatoid arthritis Ushering in a new era
Review Article Outcomes Research in Rheumatoid arthritis Ushering in a new era *Suseem 1, Emily James 1,2, Mathew George 2 * Assistant Professor Senior, School of Advanced Sciences (SAS), Vellore Institute
More informationG Wells, 1 J-C Becker, 2 J Teng, 2 M Dougados, 3 M Schiff, 4 J Smolen, 5 D Aletaha, 6 P L C M van Riel 7. Extended report
1 Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Canada; 2 Bristol-Myers Squibb, Princeton, New Jersey, USA; 3 Paris-Descartes University, Medicine Faculty and UPRES-EA
More informationT. Pincus 1, B. Richardson 2, V. Strand 3, M.J. Bergman 4
Relative efficiencies of the 7 rheumatoid arthritis Core Data Set measures to distinguish active from control treatments in 9 comparisons from clinical trials of 5 agents T. Pincus 1, B. Richardson 2,
More informationElevated risk of tuberculosis in patients with rheumatoid arthritis in Japan
ARD Online First, published on July 12, 2006 as 10.1136/ard.2005.047274 Concise report Elevated risk of tuberculosis in patients with rheumatoid arthritis in Japan Toru Yamada, Ayako Nakajima, Eisuke Inoue,
More informationAssessing Disease Activity in Psoriatic Arthritis: A Literature Review
Rheumatol Ther (2019) 6:23 32 https://doi.org/10.1007/s40744-018-0132-4 REVIEW Assessing Disease Activity in Psoriatic Arthritis: A Literature Review Laura J. Tucker. Laura C. Coates. Philip S. Helliwell
More informationTHE PATIENT S PERSPECTIVE ON PSORIATIC ARTHRITIS: WHAT MORE CAN RHEUMATOLOGISTS DO TO OPTIMISE DISEASE MANAGEMENT?
THE PATIENT S PERSPECTIVE ON PSORIATIC ARTHRITIS: WHAT MORE CAN RHEUMATOLOGISTS DO TO OPTIMISE DISEASE MANAGEMENT? This symposium took place on 16 th June 2017 as a part of the European League Against
More informationEfficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis
To cite: Fleischmann RM, Huizinga TWJ, Kavanaugh AF, et al. Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. RMD Open 2016;2:e000262. doi:10.1136/rmdopen-2016-000262
More informationVectra DA for the objective measurement of disease activity in patients with rheumatoid arthritis
Vectra DA for the objective measurement of disease activity in patients with rheumatoid arthritis O.G. Segurado, E.H. Sasso Crescendo Bioscience, South San Francisco, United States. Oscar G. Segurado,
More informationOpen Access NY, USA. Keywords: HAQ, early RA, disease activity, DAS, cohort, correlation, longitudinal.
Send Orders for Reprints to reprints@benthamscience.net 58 The Open Rheumatology Journal, 2013, 7, 58-63 Open Access The Relationship Between Function and Disease Activity as Measured by the HAQ and DAS28
More informationIdentifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set
To cite: Bykerk VP, Bingham CO, Choy EH, et al. Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set. RMD Open 2016;2:e000225. doi:10.1136/rmdopen-2015-000225
More informationClinical Policy: Certolizumab (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Cimzia ) is a tumor necrosis
More informationLearned helplessness predicts functional disability, pain and fatigue in patients with recent-onset inflammatory polyarthritis
RHEUMATOLOGY Rheumatology 2013;52:1233 1238 doi:10.1093/rheumatology/kes434 Advance Access publication 18 February 2013 Original article Learned helplessness predicts functional disability, pain and fatigue
More informationStudy synopsis of the global non-interventional study SWITCH-RA
Study synopsis of the global non-interventional study SWITCH-RA Protocol number: MA22401 Title of Study: A global multi-centre observational study in RA patients who are non-responders or intolerant to
More informationThe METEOR initiative: the way forward for optimal, worldwide data integration to improve care for RA patients
The METEOR initiative: the way forward for optimal, worldwide data integration to improve care for RA patients R. van den Berg 1, D. van der Heijde 1, R. Landewé 2,3, K. van Lambalgen 4, T. Huizinga 1,
More informationNEW EFFECTIVE TREATMENTS FOR PSORIATIC ARTHRITIS PATIENTS Promising data to support two new drug classes
Annual European Congress of Rheumatology (EULAR) 2017 Madrid, Spain, 14-17 June 2017 NEW EFFECTIVE TREATMENTS FOR PSORIATIC ARTHRITIS PATIENTS Promising data to support two new drug classes Madrid, Spain,
More informationNo choice of outcomes about us without us Patient and public involvement in core outcome set development. Paula Williamson
No choice of outcomes about us without us Patient and public involvement in core outcome set development Paula Williamson Core Outcome Measures in Effectiveness Trials www.comet-initiative.org DMARD trials
More informationI nuovi criteri ACR/EULAR per la classificazione dell artrite reumatoide
I nuovi criteri ACR/EULAR per la classificazione dell artrite reumatoide Pierluigi Macchioni Struttura Complessa di Reumatologia, Ospedale di Reggio Emilia Topics 1987 ACR classification criteria for RA
More informationThe Relationship Between Disease Activity and Radiologic Progression in Patients With Rheumatoid Arthritis
ARTHRITIS & RHEUMATISM Vol. 50, No. 7, July 2004, pp 2082 2093 DOI 10.1002/art.20350 2004, American College of Rheumatology The Relationship Between Disease Activity and Radiologic Progression in Patients
More informationEfficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
New Evidence reports on presentations given at EULAR 2010 Efficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2010 presentations
More informationBMJ Open. Long-term sustained remission in a cohort study of patients with rheumatoid arthritis choice of remission criteria.
BMJ Open Long-term sustained remission in a cohort study of patients with rheumatoid arthritis choice of remission criteria. Journal: BMJ Open Manuscript ID: bmjopen--00 Article Type: Research Date Submitted
More informationCRITICALLY APPRAISED PAPER (CAP)
CRITICALLY APPRAISED PAPER (CAP) Masiero, S., Boniolo, A., Wassermann, L., Machiedo, H., Volante, D., & Punzi, L. (2007). Effects of an educational-behavioral joint protection program on people with moderate
More informationNewer classification criteria 2010:How adequate is this to classify Rheumatoid Arthritis?
Newer classification criteria 2010:How adequate is this to classify Rheumatoid Arthritis? DR MD MATIUR RAHMAN MBBS, MD, FCPS, FACR, Fellow APLAR Associate Professor, Medicine SSMC & Mitford Hospital New
More informationPain, sleep and emotional well-being explain the lack of agreement between physician- and patient-perceived remission in early rheumatoid arthritis
Turk et al. BMC Rheumatology (2018) 2:16 https://doi.org/10.1186/s41927-018-0024-9 BMC Rheumatology RESEARCH ARTICLE Open Access Pain, sleep and emotional well-being explain the lack of agreement between
More informationR heumatoid arthritis is a chronic debilitating disease that
924 EXTENDED REPORT Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment K Laas, R Peltomaa, H Kautiainen, K Puolakka, M Leirisalo-Repo... Ann
More informationArthritis Research & Therapy 2014, 16:R56
Arthritis Research & Therapy This Provisional PDF corresponds to the article as it appeared upon acceptance Copyedited and fully formatted PDF and full text (HTML) versions will be made available soon
More informationIntroduction ORIGINAL ARTICLE
Mod Rheumatol (2007) 17:28 32 Japan College of Rheumatology 2007 DOI 10.1007/s10165-006-0532-0 ORIGINAL ARTICLE Hisashi Yamanaka Yoshiya Tanaka Naoya Sekiguchi Eisuke Inoue Kazuyoshi Saito Hideto Kameda
More informationTreatment of Rheumatoid Arthritis: The Past, the Present and the Future
Treatment of Rheumatoid Arthritis: The Past, the Present and the Future Lai-Ling Winchow FCP(SA) Cert Rheum(SA) Chris Hani Baragwanath Academic Hospital University of the Witwatersrand Outline of presentation
More informationThe new ACR/EULAR remission criteria: rationale for developing new criteria for remission
RHEUMATOLOGY Rheumatology 2012;51:vi16 vi20 doi:10.1093/rheumatology/kes281 The new ACR/EULAR remission criteria: rationale for developing new criteria for remission Vivian P. Bykerk 1,2 and Elena M. Massarotti
More informationGolimumab: a novel anti-tumor necrosis factor
Golimumab: a novel anti-tumor necrosis factor Rossini M, De Vita S, Ferri C, et al. Biol Ther. 2013. This slide deck represents the opinions of the authors, and not necessarily the opinions of the publisher
More informationDepartment of Rheumatology, Polytechnic University of Marche, Ancona, Italy; 2
Disease activity assessment of rheumatoid arthritis in daily practice: validity, internal consistency, reliability and congruency of the Disease Activity Score including 28 joints (DAS28) compared with
More informationPatient Discussion Guide: UNDERSTANDING FIBROMYALGIA HOW TO MANAGE IT&
Patient Discussion Guide: UNDERSTANDING FIBROMYALGIA HOW TO MANAGE IT& FM OVERVIEW 2 What is Fibromyalgia? Reinforce that Fibromyalgia (FM) is a chronic widespread pain condition 1,2 Reassure the patient
More informationChapter 4. Advances in Rheumatology 2004 volume 2
Chapter 4 Sustained remission in a cohort of patients with rheumatoid arthritis: association with absence of IgM rheumatoid factor and absence of anti-ccp antibodies. Advances in Rheumatology 2004 volume
More informationThe long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study
RHEUMATOLOGY Rheumatology 2011;50:1106 1110 doi:10.1093/rheumatology/keq424 Advance Access publication 21 January 2011 Concise report The long-term impact of early treatment of rheumatoid arthritis on
More informationT. Uhlig, E. A. Haavardsholm and T. K. Kvien
Rheumatology 2006;45:454 458 Advance Access publication 15 November 2005 Comparison of the Health Assessment Questionnaire (HAQ) and the modified HAQ (MHAQ) in patients with rheumatoid arthritis T. Uhlig,
More informationVectra DA Blood Test for Rheumatoid Arthritis
Medical Policy Manual Laboratory, Policy No. 67 Vectra DA Blood Test for Rheumatoid Arthritis Next Review: June 2019 Last Review: June 2018 Effective: August 1, 2018 IMPORTANT REMINDER Medical Policies
More informationABSTRACT ORIGINAL RESEARCH
https://doi.org/10.1007/s40744-018-0113-7 ORIGINAL RESEARCH Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan
More informationReview. Structural progression in rheumatoid arthritis remission: can MRI predict it? Frederique Gandjbakhch*1 & Violaine Foltz1
Structural in rheumatoid arthritis remission: can MRI predict it? Remission has become an achievable goal in rheumatoid arthritis (RA) thanks to a large choice of drug therapies and improvement of treatment
More informationEffectiveness and safety profile of leflunomide in rheumatoid arthritis: actual practice compared with clinical trials
Effectiveness and safety profile of leflunomide in rheumatoid arthritis: actual practice compared with clinical trials K. Martin 1, F. Bentaberry 2, C. Dumoulin 2, J. Dehais 2, F. Haramburu 1, B. Bégaud
More informationNottingham health profile questionnaire incorporates important aspects of the patient perspective into outcome assessment in rheumatoid arthritis
Nottingham health profile questionnaire incorporates important aspects of the patient perspective into outcome assessment in rheumatoid arthritis T. Uutela 1,2, H. Kautiainen 3, M. Hakala 3,4 1 Department
More informationTofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve and Experienced Patients
doi: 10.2169/internalmedicine.9341-17 Intern Med Advance Publication http://internmed.jp ORIGINAL ARTICLE Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve
More informationPrediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial
Original article Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial Psoriatic arthritis Philip J Mease, 1 Arthur Kavanaugh,
More informationThis is a repository copy of New GRAPPA and EULAR recommendations for the management of psoriatic arthritis: process and challenges faced.
This is a repository copy of New GRAPPA and EULAR recommendations for the management of psoriatic arthritis: process and challenges faced. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/102808/
More informationPress Release. The key findings from the research were:
Press Release Sanofi and NRAS launch RefRAme the Future campaign to highlight the importance of mental strength in helping people with rheumatoid arthritis (RA) better manage their condition New campaign
More informationOptimal responses in disease activity scores to treatment in rheumatoid arthritis: Is a DAS28 reduction of >1.2 sufficient?
Mian et al. Arthritis Research & Therapy (2016) 18:142 DOI 10.1186/s13075-016-1028-8 RESEARCH ARTICLE Optimal responses in disease activity scores to treatment in rheumatoid arthritis: Is a DAS28 reduction
More informationABSTRACT INTRODUCTION. Joseph Markenson, MD, 1 Kathryn Charalambous, PhD, 2 Christopher Viereck, PhD, CCMEP, 3 Derek Dietze, MA, FACEHP, CCMEP 3
US Rheumatologists Attitudes, Practice Habits, Barriers, and Knowledge Gaps in Assessing and Monitoring Patients with Rheumatoid Arthritis according to Recent Recommendations Joseph Markenson, MD, 1 Kathryn
More information